Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a reiterated with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.92, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/15/2023 | 628.26% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 628.26% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 2291.3% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 117.39% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 117.39% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 171.74% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 117.39% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 443.48% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 769.57% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 660.87% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 02/15/2023 | 628.26% | EF Hutton | → 6.7 美元 | 重申 | → 购买 |
| 2022 年 12 月 19 日 | 628.26% | EF Hutton | → 6.7 美元 | 开启覆盖范围 | → 购买 |
| 09/22/2022 | 2291.3% | 查丹资本 | 2 美元 → 22 美元 | 维护 | 买 |
| 08/16/2022 | 117.39% | 查丹资本 | 2.5 美元 → 2 美元 | 维护 | 买 |
| 02/09/2022 | 117.39% | BTIG | 5 美元 → 2 美元 | 维护 | 买 |
| 2021 年 12 月 20 日 | 171.74% | 查丹资本 | 8 美元 → 2.5 美元 | 维护 | 买 |
| 2021 年 12 月 16 日 | 117.39% | HC Wainwright & Co. | → 2 美元 | 开启覆盖范围 | → 购买 |
| 09/15/2021 | 443.48% | BTIG | → 5 美元 | 开启覆盖范围 | → 购买 |
| 09/04/2020 | 769.57% | 查丹资本 | 7 美元 → 8 美元 | 维护 | 买 |
| 06/05/2020 | 660.87% | 查丹资本 | → 7 美元 | 开启覆盖范围 | → 购买 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的目标价格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by EF Hutton on February 15, 2023. The analyst firm set a price target for $6.70 expecting SONN to rise to within 12 months (a possible 628.26% upside). 4 analyst firms have reported ratings in the last year.
EF Hutton于2023年2月15日公布了Sonnet BioTherapeutics（纳斯达克股票代码：SONN）的最新目标股价。这家分析公司将目标价设定为6.70美元，预计SONN将在12个月内升至628.26％（可能上涨628.26％）。去年，有4家分析公司公布了评级。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的最新分析师评级是多少？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by EF Hutton, and Sonnet BioTherapeutics reiterated their buy rating.
Sonnet BioTherapeutics（纳斯达克股票代码：SONN）的最新分析师评级由EF Hutton提供，Sonnet BioTherapeutics重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与Sonnet BioTherapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。Sonnet BioTherapeutics的最新评级是在2023年2月15日公布的，因此你应该预计下一个评级将在2024年2月15日左右公布。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析师对Sonnet BioTherapeutics（SONN）的评级正确吗？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a reiterated with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.92, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Sonnet BioTherapeutics（SONN）评级得到了重申，目标价为0.00美元至6.70美元。Sonnet BioTherapeutics（SONN）目前的交易价格为0.92美元，在分析师的预测区间内。
